Panacea Journal of Medical Sciences 2024;14(1):292–300

Content available at: https://www.ipinnovative.com/open-access-journals

Panacea Journal of Medical Sciences

Journal homepage: http://www.pjms.in/

Original Research Article

Arginine in sickle cell vaso-occlusive crisis: A randomised placebo control trial

Subash Chandra Majhi[1], Himansu Nayak[1], Sameer Kiro[1], Santosh Patil[1], Shitanshu Kumar Meher[1], Sanjukta Panda[1], Mangal Charan Murmu[1]*

[1] *Dept. of Pediatrics, Veer Surendra Sai Institute of Medical Sciences and Research, Sambalpur, Odisha, India*

ARTICLE INFO

Article history:
Received 16-04-2021
Accepted 07-07-2022
Available online 13-03-2024

Keywords:
Sickle cell disease
Arginine
Vaso-occlusive crisis

ABSTRACT

Introduction: Sickle cell disease is one of the most common hemoglobinopathies in India. A vaso-occlusive crisis is one of the most common indications for hospitalization, it accounts for 70% of hospitalization.

Aim & Objective: To compare efficacy of Arginine in vaso-occlusive episode(VOE) management in terms of mean fall in pain score at discharge between intervention (Arginine) & placebo group among sickled children with skeletal vaso-occlusive crisis between 2-14 years of age.

Materials and Methods: This randomized placebo control study was carried out after getting clearance from the institutional ethical & research committee, from November 2019 to October 2021 in the Indoor of Pediatrics Department, Veer Surendra Sai Institute of Medical Science (VIMSAR), Burla, Sambalpur.

Observation: There is significant fall in pain score in case group as compared with control group as evidenced by p value being less than 0.001, indicating that l-arginine has significant role in reducing sickle cell vaso-occlusive episode. Mean Length of stay (LOS) in hospital in case group was 2.16, while in control group was 2.69. p value being calculated showed the value to be less than 0.001, which shows importance of l-arginine in reducing in mean length of stay in hospitalization.

Conclusion: L-arginine plays a vital role in treating vaso-occlusive episodes. It helps to reduce the pain gradually as evidenced by noting down pain score at the time of admission & every 24 hours of therapy till discharge. It also helps to reduce the mean duration of hospitalization in vaso-occlusive episode.

1. Introduction

Pain is the hall mark of vaso-occlusive crisis & accounts for about 70% of hospitalizations in Sickle Cell Disease(SCD) patients.[1] Nationally,78% of the nearly 200,0000 annual emergency department visit for SCD are for a complaint of pain, yet there is no effective therapy that targets the underlying mechanisms of VOE.[2] Vaso-occlusion leads to organ damage, a decreased quality of life, & a decreased life expectancy in patients with sickle cell disease (SCD).[3] Dactylics, referred to as hand-foot syndrome, is often the first manifestation of pain in infants & young children with sickle cell anemia.[4,5] Arginase is released from ruptured erythrocytes, platelets, & the liver.[6–9]

Arginine is a fundamental compound for the development of nitric oxide (NO), which is an intense vasodilator.[10] It is diminished in SCD patients, which might cause hindrance in the microcirculation, repetitive agony, and hospitalization, with expanded Arginine accessibility, there is more prominent NO unions, which prompts further developed microcirculation and patient clinical profiles.[11]

* *Corresponding author*.
E-mail address: mangal74murmu@yahoo.co.in (M. C. Murmu).

https://doi.org/10.18231/j.pjms.2024.052

Vasculopathy, a significant reason for dreariness and mortality in sickle-cell disease,[12] is related with endothelial brokenness. This brokenness incorporates expanded endothelial cell initiation and bond, unusual tone, responsiveness, and vessel architecture,[13] which can be upset by intravascular haemolysis, expanded oxidative pressure, and diminished nitric oxide bioavailability. Arginase is set free from burst erythrocytes, platelets, and the liver. High groupings of arginase lessen plasma arginine, the sole substrate of endothelial nitric oxide synthase, in this manner diminishing nitric oxide production.[14]

During hemolysis, arginase as compound that utilizes L-arginine and adds to a diminishing in NO fixation in SCA patients, is delivered. Different examinations have shown that NO is a cofactor for the protein guanvate cycles which is liable for the transformation of guano sine triphosphate (GTP) to cyclic guanine monophosphate (cGMP). cGMP is liable for smooth and vascular muscle unwinding and vasodilation. The most reduced arginine level were found in kids requiring confirmation for VOE, with arginine levels getting back to benchmark during recovery in the hospital.[2] An expanded compensatory interest for NO in bringing about diminished L-Arg and NO levels during VOE.[15] L-arginine levels are discouraged in patients with sickle cell illness, especially during vaso-occlusive torment crisis.[16] When a solitary portion of arginine is given to patients with SCD during VOE, there is a powerful portion subordinate expansion in plasma NO.[2]

Diminished nitric oxide bioavailability is embroiled in the pathophysiology of a few problems including endothelial capability, including sickle-cell illness, hypertension, and persistent kidney sickness. Further developing arginine fixations could further develop results in these disorders[14] so this study was done.

2. Aim & Objective

2.1. Primary objective

1. To compare efficacy of Arginine in VOE management in terms of mean fall in pain score at discharge between intervention (Arginine) & placebo group among sickled children with skeletal vaso-occlusive crisis between 2-14years of age.
2. To estimate Relative Risk (RR), Number Needed to Treat (NNT) among two group of sickle children aged between 2-14 years with skeletal vaso-occlusive crisis.
3. To compare the mean duration of hospitalization among intervention & placebo in sickled children between 2-14years of age.

2.2. Secondary objective

To find out adverse events to Arginine Therapy.

3. Materials and Methods

After getting clearance from the institutional ethical & research committee, the study was carried out from November 2019 to October 2021 in the Indoor of Pediatrics Department, Veer Surendra Sai Institute of Medical Science (VIMSAR), Burla, Sambalpur. It's location is 21°29´38.88" N 83°53´10.06" E, where the incidence of sickle cell disease is high. It was randomized placebo control trial.

3.1. Study population

Case of Sickle Cell homozygous children attending our in Patient Department /Out Patient Department with complaint of Skeletal vaso-occlusive crisis.

3.2. Inclusion criteria

1. HPLC Confirmed case of homozygous sickle cell anemia
2. Children between 2-14 years of age
3. Either gender
4. Clinically Diagnosed Skeletal Vaso-Occlusive Episode defined as bone pain typical of sickle crisis which is no associated to any other cause.

3.3. Exclusion criteria

1. Critically ill patient
2. Presence of renal disease
3. Presence Hepatic disease
4. On Arginine Therapy in last three months

3.4. Sample size estimation

Sample size is estimated by n master 2.0(BRTC Vellore) based upon clinical trial -parallel design -superiority trial -hypothesis testing for 2 means. Based on previous study (1) SD of arginine group =2.4, SD of placebo group 2=2.9, Mean difference = 2, Then taking alpha(type1) error as 5% , power (1-ß) as 80, minimum sample size calculated to be 28 in each group. Adding 15% for attrition, total sample size is (32+32)=64 in total.

Weight, height is measured & BMI is calculated. Routine investigations are sent which includes complete blood count (CBC), Renal function test – Sr urea & creatinine, Liver function test (LFT)- Sr total & direct bilirubin, AST(Aspartate transaminase), ALT (Alanine transaminase), ALP (Alkaline phosphatase). If any abnormality is noted in LFT (Liver Function Test), RFT (Renal Function Test), or if the patient is critically ill then they are not taken into study. Pain score is noted during admission by Wong Baker Faces pain rating scale for children between 2 to 8 year or visual analogue scale for children between 8 to 14 year. Written informed consent is taken & the same is explained to guardian of child. He will be randomized by computer generated mixed block randomization, then

he will allocated by double opaque sealed envelope. Later drug or placebo is being by single blinding. Drug masking done on basis of colour, flavor, texture, size, quantity. Placebo being ORS(Oral Rehydration solution) sachet. Both Arginine sachet & ORS sachet are mixed in 200ml of water in the ward by nursing staff which will be served to the patient as per predefined test. Arginine is given @ a dose of 100mg/kg/dose three times a day with a maximum dose of 10gm for 15 doses or until discharge whichever occurs first. Pain score is noted every day till the discharge.

3.5. Data analysis

The data were tabulated in Microsoft excel version 16 & was analyzed in SPSS version 21. All the quantitative variables were expressed in mean & standard deviation & categorial variables were expressed in proportion & percentages.

For statistical analysis, unpaired t test was used to compare between two means & chi square root test was used to compare the proportions between the groups.

With 95% CI, the p value less than 0.05 was considered significance. All the PPA(Per protocol analysis) will be done. Continues data will be expressed as mean +/- SD. Categorical data will be expressed by proportion T test will be used for analysis of continues data. Fisher exact t test will be used for analysis of categorical data. Risk ratio (RR), Number needed to treat (NNT) will be done by 2×2 contingency table for all statistical p value.

4. Observation

A randomized control trail was conducted in the In-Patient Department (IPD) of Pediatric Department of a tertiary Medical College Hospital Veer Surendra Sai Institute Of Medical Science & Research Center, Burla, Odisha, India enrolling 64 child patients aged between 2 year to 14years by random sampling with inclusion criteria. Patients were enrolled & randomly allocated into intervention & control group by randomization by computer generated mixed block randomization. Pain was measured at the time of hospitalization with help of Wong Baker Faces Scale (WBS) for children between 2-8 years of age & Visual Analog Scale (VAS) Pain Score for children between 8-14 years of age.

Treatment was initiated in the form of case group receiving oral L-argininesachet, Control group was probiotic sachet. L-arginine & probiotic sachet were being mixed with 200ml of water & being served to the patient. L-arginine was at dose of 100mg/kg/dose three times a day with maximum dose of 10gm for 15 doses or untill discharge whichever occurs first. Control group was given probiotic sachet.

All the patient were monitored as regard pain severity after 24hour of oral therapy till pain relief & discharge. The relevant data including demographic characters like age, gender, HbS %, previous history of vaso occlusive crisis, treatment with hydroxyurea is collected &analyzed.

The above table shows age wise distribution of total cases admitted with sickle cell VOC. Age group between 6-10year contributes to majority of cases with 55%, least being 11-14 year age group which contributes to 10%, 2-5year age group contributes to 35%. Table 1

Age group between 6-10year contributes to majority of cases with 55%, least being 11-14 year age group which contributes to 10%, 2-5year age group contributes to 35%. Comparison of mean weight of the study participants between two groups, maximum number of patient had weight between 21-25kg, while patient between 26-30 & 31-35kg were comparatively less. Most (42.2%) of SCD patients had height measuring between 101-120cm, height between 141-160cm is very less (6.2%). Majority (65.1%) of SCD patient had BMI ranging from 16-18, followed by 13-15(22.2%) & 19-21(12.7%). As far as socioeconomic level is concerned majority falls on upper middle & lower middle groups (31.2%).Table 2

The table signifies that most of patient had 3-4episodes of hospitalization for VOC in the past. Majority of SCD patients had severe pain during admission as evidenced by pain score ranging from 7-9(45.3%) followed by 4-6(37.5%) & 1-3(17.2%) during admission. All SCD patients were using hydroxyurea.Table 3

Most of SCD had HbS % from 56-60% (35%) followed by 61-65 %(23.4%). Majority of SCD had TLC from 8000-10999per mm3(40.6%) & 11000-15000per mm3(39.1%). Most of SCD patient had haemoglobin concentration between 7.1-8gm/dl(50%) followed by 8.1-9gm/dl(45.3%). The mean LFT profile of among two study groups, which shows mean LFT profile within normal limit for choicing patient for study group. All the SCD patient had renal profile within normal limit with majority of patient having Sr.creatinine level between 0.6-0.8mg/dl (53.1%), followed by 0.3-0.5mg/dl(39.1%)Comparison of efficacy of Arginine in VOC management in term of post-interventional outcomes.Table 4

Mean fall in pain score in case group is 5.09 as compared to 3.59 in control group with P value less than 0.001 which shows significant reduction in pain score in case group. There was significant reduction in pain score in case group at 24hr, 48hr & 72hr with P value less than 0.05.Table 5

Mean length of hospital stay in case group is 2.16, while in control group it is 2.69, which shows significant reduction in length score in case group. The case group had maximum hospitalization till day2 while control had maximum hospitalization till day 3. To evaluate the role of Arginine therapy in relieving the pain, the time require to reduce the pain was considered as marker & hence, duration of hospital stay. If the duration of hospital stay was less than or equal to 2 days, it was considered success & more then 2 days was considered failure.Table 6

Table 1: Socio-demographic profile of the study participants

Parameter		Overall (N=64)
Age	Mean	6.88
Age group	2-5 yrs	22 (34.4%)
	6-10 yrs	35 (54.7%)
	11-14 yrs	7 (10.9%)
Sex	Female	19 (29.7%)
	Male	45 (70.3%)
Weight	Mean	22.67 kg
Height	Mean	115.22 cm
BMI	Mean	16.55
Socioeconomic status	L	8 (12.5%)
	LM	17 (26.6%)
	UL	15 (23.4%)
	UM	21 (32.8%)
	U	3 (4.7%)

Table 2: Comparison of the study participants betweencase & control groups

Parameter		Case (N=32)	Control (N=32)	Total (N=64)	P value
Age group	2-5 yrs	11 (34.4%)	11 (34.4%)	22 (34.4%)	0.92
	6-10 yrs	17 (53.1%)	18 (56.2%)	35 (54.7%)	
	11-14 yrs	4 (12.5%)	3 (9.4%)	7 (10.9%)	
Sex	Female	7 (21.9%)	12 (37.5%)	19 (29.7%)	0.17
	Male	25 (78.1%)	20 (62.5%)	45 (70.3%)	
Weight	9-15 kg	6 (9.4%)	7 (10.9%)	13 (20.3%)	0.98
	16-20 kg	7 (10.9%)	5 (7.8%)	12 (18.8%)	
	21-25kg	9(14.1%)	10(15.6%)	19(29.7%)	
	26-30 kg	5 (7.8%)	5 (7.8%)	10 (15.6%)	
	31-35 kg	5 (7.8%)	5 (7.8%)	10 (15.6%)	
Height	80-100 cm	6 (9.4%)	7 (10.9%)	13 (20.3%)	0.99
	101-120 cm	14 (21.9%)	13 (20.3%)	27 (42.2%)	
	121-140 cm	10 (15.6%)	10 (15.6%)	20 (31.2%)	
	141-160 cm	2 (3.1%)	2 (3.1%)	4 (6.2%)	
BMI(kg/m2)	13-15	7 (11.1%)	7 (11.1%)	14 (22.2%)	1.0
	16-18	20 (31.7%)	21 (33.3%)	41 (65.1%)	
	19-21	4 (6.3%)	4 (6.3%)	8 (12.7%)	
Socioeconomic status	L	5 (15.6%)	3 (9.4%)	8 (12.5%)	0.73
	LM	10 (31.2%)	7 (21.9%)	17 (26.6%)	
	UL	6 (18.8%)	9 (28.1%)	15 (23.4%)	
	UM	10 (31.2%)	11 (34.4%)	21 (32.8%)	
	U	1 (3.1%)	2 (6.2%)	3 (4.7%)	

Table 3: Comparison of clinical profile of study participants

Parameter		Case (N=32)	Control (N=32)	Total (N=64)	P value
Past History of Hospitalization (Frequency)	0-2	9 (14.1%)	4 (6.2%)	13 (20.3%)	0.27
	3-4	20 (31.2%)	23 (35.9%)	43 (67.2%)	
	5-6	3 (4.7%)	5 (7.8%)	8 (12.5%)	
VOC_type	Mild	7 (21.9%)	8 (25.0%)	15 (23.4%)	0.71
	Mod	14 (43.8%)	16 (50.0%)	30 (46.9%)	
	Severe	11 (34.4%)	8 (25.0%)	19 (29.7%)	
Pt_using_Hydroxyurea	Yes	32 (50.0%)	32 (50.0%)	64 (100.0%)	1.0
Pain_Score_admission	1-3	5 (7.8%)	6 (9.4%)	11 (17.2%)	0.44
	4-6	10 (15.6%)	14 (21.9%)	24 (37.5%)	
	7-9	17 (26.6%)	12 (18.8%)	29 (45.3%)	

Table 4: Comparison of blood investigation between two groups

Parameter			Case (N=32)	control (N=32)	Total (N=64)	P value
HbS (%) Distribution		50-55	5 (7.8%)	7 (10.9%)	12 (18.8%)	0.49
		56-60	17 (26.6%)	18 (28.1%)	35 (54.7%)	
		61-65	8 (12.5%)	7 (10.9%)	15 (23.4%)	
		66-70	2 (3.1%)	0 (0.0%)	2 (3.1%)	
TLC(per mm3)		5000-7999	10 (15.6%)	3 (4.7%)	13 (20.3%)	0.085
		8000-10999	12 (18.8%)	14 (21.9%)	26 (40.6%)	
		11000-15000	10 (15.6%)	15 (23.4%)	25 (39.1%)	
Hb(gm/dl)		6-7	2 (3.1%)	1 (1.6%)	3 (4.7%)	0.83
		7.1-8	16 (25.0%)	16 (25.0%)	32 (50.0%)	
		8.1-9	14 (21.9%)	15 (23.4%)	29 (45.3%)	
Sr.Creatinine(mg/dl)		0.3-0.5	12 (18.8%)	13 (20.3%)	25 (39.1%)	0.38
		0.6-0.8	16 (25.0%)	18 (28.1%)	34 (53.1%)	
		0.9-1.1	4 (6.2%)	1 (1.6%)	5 (7.8%)	
LFT profile	Bilirubin_T	Mean	1.04	0.98	1.01	0.25
	Bilirubin_D	Mean	0.26	0.28	0.27	0.29
	SGOT	Mean	45.59	45.91	45.75	0.88
	SGPT	Mean	31.81	41.22	36.52	<0.001

Table 5: Comparison of pain score fall between two intervention groups

Pain score fall		Case (N=32)	control (N=32)	Total (N=64)	P value
	Mean	5.09	3.59	4.34	<0.001
at 24hr class	1-2	12 (19.4%)	26 (41.9%)	38 (61.3%)	<0.001
	2-3	12 (19.4%)	2 (3.2%)	14 (22.6%)	
	3-4	7 (11.3%)	3 (4.8%)	10 (16.1%)	
48hrclass	1-2	22 (34.9%)	28 (44.4%)	50 (79.4%)	0.095
	2-3	9 (14.3%)	3 (4.8%)	12 (19.0%)	
	3-4	1 (1.6%)	0 (0.0%)	1 (1.6%)	
72hr class	1-2	24 (49.0%)	24 (49.0%)	48 (98.0%)	0.32
	2-3	0 (0.0%)	1 (2.0%)	1 (2.0%)	

Table 6: Comparison of post intervention length of hospital stay between two groups

		Case (N=32)	control (N=32)	Total (N=64)	P value
	Mean	2.16	2.69	2.42	<0.001
Days stay	1	6 (9.4%)	2 (3.1%)	8 (12.5%)	<0.001
	2	15 (23.4%)	6 (9.4%)	21 (32.8%)	
	3	11 (17.2%)	24 (37.5%)	35 (54.7%)	

Table 7: Illustrate the comparison of success & failure among intervention & control group

Outcome	Arginine	Control	Total	P
Failure	11 (34.3%)	24 (75%)	35 (54.6%)	
Success	21 (65.7%)	8 (25%)	29(45.4%)	0.001097
Total	32 (100%)	32 (100%)		

The success rate with arginine was very good as indicated by the p value of 0.001097 without any side effect. Table 7

Outcome + Outcome - Total Inc risk * Odds

Exposed + 11 24 35 31.4 0.458 Exposed - 21 8 29 72.4 2.625 Total 32 32 64 50.0 1.000

Point estimates & 95% CIs:

Inc risk ratio 0.43 (0.25, 0.74)

Odds ratio 0.17 (0.06, 0.52)

Attrib risk in the exposed * -40.99 (-63.37, -18.60)

Attrib fraction in the exposed (%) -130.41 (-294.77, -34.48)

Attrib risk in the population * -22.41 (-42.78, -2.05)

Attrib fraction in the population (%) -44.83 (-78.74, -17.35)

Uncorrected chi2 test that OR = 1: chi2(1) = 10.656 Pr>chi2 = 0.001

Fisher exact test that OR = 1: Pr>chi2 = 0.002

Wald confidence limits

CI: confidence interval * Outcomes per 100 population units

Measures of association strength: 7

Measures of effect in the exposed: 3 1

Number needed to treat for benefit (NNTB) & harm (NNTH): 5

Measures of effect in the population: 4 2

5. Discussion

Sickle cell disease is one of most common hemoglobinopathy in India. It is more prevalent in western Odisha, Maharashtra, Madhya Pradesh. Vaso-occlusive crisis in sickle cell disease is one of the most common morbidity encountered during early childhood phase of life .Vaso-occlusive crisis is one the most common indication requiring hospitalization .Number of pharmacological & non pharmacological approaches are being used for relief of pain.

As evidenced in the prevalence of vaso-occlusive crisis in Sickle cell disease patient admitted in present study is more in age group between 6-10years (54.7%) followed by 2-5years (34.4%) & 11-14years (10.9%). Studies done by Mohammed Zolaly, , Ghaidaa Al-Mohammadi et[17] all had similar finding which may be related to less knowledge about sickle cell vaso-occlusive crisis during initial few years .

The majority of sickle cell vaso-occlusive crisis is contributed by male patients (70.3%) as compared to female patients (29.7%). In current study majority of sickle cell disease patient had mean weight of 22.67. Mean weight among case group was 22.91, while mean weight among control group was 22.44. Weight for age is less than normal as compared to normal healthy patient. Malnutrition, infection, psychological effect, parents negligence towards their child may be the contributing factor for less than normal weight for age . These are finding are similar to Amanda Cristina da Silva de Jesusa, TulioKonstantyner et al.[18]

We found sickle cell disease patients had less height for age compared to normal healthy child. Mean height among case group was 115.53, while in control group was 114.91. This discrepancy is may be due to consequences of the disease, such as repetitive infections, pain, blood transfusions & frequent hospitalization which highlights the importance of inadequate nutritional support.

Since both weight & height were less than normal for age as compared to normal healthy child, BMI(Body Mass Index) of sickle cell disease patients were less than normal as per age. It can explained by undernourishment & co-morbidities associated with sickle cell disease

Most of sickle cell disease patient admitted with vaso-occlusive crisis were belonging into lower socio-economic in present study status which will effect the nutritional support, absenteeism & lower school performance. Low level of education of children's guardians, which makes it difficult to get a formal job. Thus, families are more inclined to work with informal & uncertain services, without the security of a monthly income.

In present review, just homozygous sickle cell illness patient conceded with vaso-occlusive emergency were being considered. Thus, every one of the patient had HbS rate over half. Mean HbS rate is 58.95%. Transcendent HbS % lies between56-60% (35%) trailed by 61-65 %(23.4%)&50-55% (18.8%). More the HbS%, more the possibilities of vaso-occlusive emergency.

In present review, greater part of sickle cell illness patient had previous history of hospitalization for vaso-occlusive emergency. The vast majority of sickle cell illness patient had 3-4 episode of hospitalization (67.2%), whileless than 3 episode of vaso-occlusive episode was noted 20.3%, 5-6 episode of vaso-occlusive episode was noted among 12.5% of sickle cell infection patient. These rising episodes of vaso-occlusive emergency is might be a result of expanded degree of HbS% and diminished degree of Fetal haemoglobin(HbF), more significant level of haematocrit, relationship with alpha thalassemia. Comparable finding were seen with Deepika S. Darbari, Vivien A. Sheehan, Samir K. Hotshot et al.[19]

In present review, all the sickle cell illness patients were on ordinary hydroxyurea theraphywho got conceded for vaso-occlusive emergency. Hydroxyurea is found to decrease the vaso-occlusive episodes. Hydroxyurea is found to diminish the majority of morbidities connected with sickle cell illness. Hydroxyurea stays a foundation of customary administration inferable from its oral viability and low poisonousness. The infection changing properties of hydroxyurea were at first ascribed to its capacity to actuate fetalhemoglobin and decline hemoglobin S polymerization. Other advantageous impacts have along these lines arisen including expanding complete hemoglobin levels, diminishing platelet and white platelet counts, changing articulation of bond atoms, and nitric oxide age. Comparative discoveries were seen with study done by Paolo Rigano, Lucia De Franceschi, Laura Sainati, Antonio Piga et al.[20]

Greater part of patients had complete leucocyte count running between8000-10999 cells/mm3(40.6%), 11000-15000 cells/mm3 (39.6%), followed by 5000-7999 cells/mm3 (20.3%). Endothelial brokenness and sterile irritation, which are signs of SCD, may add to upregulation of selectins (P-and E-), vascular-cell-bond atom 1 (VCAM-1), ICAM-1, and significant leukocyte chemo attractants or interleukin-8 (IL-8) on endothelial cells.[21]

Larger part of sickle cell infection patient had hemoglobin level going from 7.1-8gm/dl (half), while 45.3% patient had hemoglobin level going from 8.1-9gm/dl, not many patient had hemoglobin from 6.1-7gm/dl (4.7%). In sickle cell illness there is harm to

coursing erythrocytes happens with wide variety among people. This heterogeneity emerges from contrasts in natural attributes of sickle erythrocytes, as heterocellular fetal hemoglobin (HbF) conveyance, HbSconcentration, hydration, and thickness and the cell's ecological advances from large scale to microcirculation, laminar to fierce stream, normoxia to hypoxia, isotonic to hypertonic climate. Subsequently the greater part of sickle cell illness patient had hemoglobin levels in lower limit according to their age, orientation. These finding were like review done by Gregory J. Kato, Martin H. Steinberg, and Mark T. Gladwin.[22]

Persistent liver injury in patients with sickle cell illness is a multifactorial peculiarity relying for the most part upon covering elements like iron over-burden and viral harm as opposed to essential sickness itself. Liver Pathology found in sickle cell illness incorporates Intrasinusoidal sickling and Kupffer cell hyperplasia, hepatitis, constant latent clog, normal conduit deterrent, alcoholic liver infection, pregnancy, collagen-vascular illness and sarcoidosis. Present review doesn't corelate with study done by Emel Gürkan, Yilmaz Ergun, Suzan Zorludemir, Fikri Başlamişli, Rikkat Koçak.[23] In current review patient are chosen when there is no previous liver pathology.

Sickle cell illness patient with renal capability test inside typical breaking point, are being remembered for the current concentrate as exhibited in table 15, Majority of sickle cell infection patient had Sr creatinine level going between 0.6-0.9mg/dl (53.1%), while not very many sickle cell illness patient had Sr creatinine level going from 0.9-1.1mg/dl (7.8%), outstanding patients had Sr creatinine level going from 0.3-0.5mg/dl (39.1%). Renal contribution is normally more serious in homozygous illness (sickle cell frailty, HbSS) than in compound heterozygous sorts of SCD (for instance HbSC and HbSβ +-thalassaemia), and is commonly gentle, less pervasive, in the heterozygous state (sickle cell characteristic, HbAS). Renal inclusion contributes considerably to the lessened future of patients with SCD. Renal inclusion can happen over the lifetime of a patient with SCD. Signs like hyperfiltration, hypertrophy, and hindered urinary concentrating skill are portrayed as soon as in earliest stages. Microalbuminuria is seen in certain patients in adolescence, though haematuria and intense kidney injury (AKI) can happen at whatever stage in life. Large scale albuminuria will in general happen in ahead of schedule to center adulthood, and can be joined by relapse of the glomerular filtration rate (GFR) to the typical reach. In the later many years, the gamble of constant kidney illness (CKD), moderate decrease of GFR, and end-stage renal sickness (ESRD) increments. These discoveries were not predictable with study done by Karl A. Nath and Robert P. Hebbel[24] as the consideration measures for present review was renal capability test inside ordinary breaking point.

A large portion of sickle cell infection patient had moderate to extreme vaso-occlusive episodes. Torment in sickle cell illness typically follows the four sequential advances. The vast majority of gentle type of vaso-occlusive episodes is being overseen in home by utilizing NSAIDs (Non-Steroidal Anti Inflmmatory Drugs) and oral hydration treatment. When vaso-occlusive episode becomes insufferable, patients come to clinic, during which they are assessed for the hastening reason for vaso-occlusive episode like pallor, leucocytosis, drying out and treated appropriately. Moderate agony are dealt with powerless narcotics alongside Non-Steroidal Anti-InflmmatoryDrugs. Comparative outcomes were seen with study done by Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC et al.[25]

6. Conclusion

Sickle cell illness is perhaps of the most well-known hemoglobinopathy in India. Now and again connected with alpha, beta-thalassemia. Different co-morbidities related with sickle cell illness incorporates stroke, leg ulcers, priapism, intense chest syndrome, aplastic emergency, vaso-occlusive episode. Sickle cell infection is a condition where multisystem are impacted. It influences the renal, pneumonic, vascular framework, genitalia, appendages, cardiovascular, gastrointestinal systems. A vaso-occlusive emergency is one of the most well-known signs for hospitalization. It is encouraged by different variables like HbS polymerization, lack of hydration, stress, contamination, sickliness, openness to cool, raised neutrophil and platelet count. Milder vaso-occlusive episodes are being overseen in-home by oral NSAIDs, while a moderate and serious assortment of torment looks for hospitalization care. It normally follows 4 stages beginning from unclear agony to die down. It is all the more generally found in male kids when contrasted with female youngsters in the early age bunch. The majority of the patients were having a place into center and lower financial situations with. Most of the patient were undernourished as appeared by lower weight, level and BMI when contrasted with offspring of a similar age bunch.

Leucocyte count is elevated in sickle cell disease along with the increase in pro-inflammatory cytokines. Hemoglobin level is reduced due to intravascular hemolysis, dehydration, circulation through the microvessels. Renal involvement results in hyperfiltration, hypertrophy, & impaired urinary concentrating ability in infancy. Liver damage is caused by primary pathology in sickle cell disease, along with that liver damage is also caused by iron load & viral damage which will result in intrasinusoidal sickling & Kupffer cell hyperplasia, hepatitis, chronic passive congestion, common duct obstruction. Hydroxyurea is a cornerstone in sickle cell disease which helps to prevent the co-morbidities related to sickle cell disease, it is recommended to start hydroxyurea therapy from 9 months

of age. It acts by various mechanisms like enhancing HbF, reducingHbS polymerization, release NO.

L-arginine plays a vital role in treating vaso-occlusive episodes. It acts by releasing nitric oxide from endothelium thereby resulting in vasodilatation. It helps to reduce the pain gradually as evidenced by noting down pain score at the time of admission & every 24 hours of therapy till discharge. It also helps to reduce the mean duration of hospitalization in vaso-occlusive episode

7. Authors' Contribution

Subas Chandra Majhi - Study concept, Research design; Santosh Patil - Literature, Data collection; Himanshu Nayak - Data compilation, Method; Sameer Kiro - Data analysis, Method, Sitanshu Kumar Meher - Method, design; Mangal Charan Murmu - Manuscript preparation & Editing, Coordination

8. Source of Funding

None.

9. Conflict of Interest

None.

References

1. Yusuf HR, Atrash HK, Grosse SD, Parker CS, Grant AM. Emergency department visits made by patients with sickle cell disease: A descriptive study. *Am J Prev Med*. 1999;38(4):S536–41.
2. Serjeant GR. The natural history of sickle cell disease. *Cold Spring Harb Perspect Med*. 2013;3(10):a011783. doi:10.1101/cshperspect.a011783.
3. Morris CR, Kuypers FA, Lavrisha L, Ansari M, Sweeters N, Stewart M, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. *Haematologica*. 2013;98(9):1375–82.
4. Onalo R, Cilliers A, Cooper P. Impact of oral L-arginine supplementation on blood pressure dynamics in children with severe sickle cell vaso-occlusive crisis. *Am J Cardiovasc Dis*. 2021;11(1):136–47.
5. Ballas SK. Pain management of sickle cell disease. *Hematol Oncol Clin North Am*. 2005;19(5):785–802.
6. Raghavachari N, Xu X, Harris A, Villagra J, Logun C, Barb J, et al. Amplified Expression Profiling of Platelet Transcriptome Reveals Changes in Arginine Metabolic Pathways in Patients With Sickle Cell Disease. *Circulation*. 2007;115(12):1551–62.
7. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. *JAMA*. 2005;294(1):81–90.
8. Vanderjagt DJ, Kanellis GJ, Isichei C, Patuszyn A, Glew RH. Serum and urinary amino acid levels in sickle cell disease. *J Trop Pediatr*. 1997;43(4):220–5.
9. Cox SE, Makani J, Komba AN, Soka D, Newton CR, Kirkham FJ, et al. Global arginine bioavailability in Tanzanian sickle cell anaemia patients at steady-state: a nested case control study of deaths versus survivors. *Br J Haematol*. 2011;155(4):522–4.
10. Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. *J Pediatr Hematol Oncol*. 2000;22(6):515–20.
11. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. *Lancet*. 2010;376(9757):2018–31.
12. Hebbel RP. Special issue of Microcirculation: examination of the vascular pathobiology of sickle cell anemia. Foreword. *Microcirculation*. 2004;11(2):99–100.
13. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. *Am J Hematol*. 2009;84(9):618–25.
14. Cox SE, Ellins EA, Marealle AI, Newton CR, Soka D, Sasi P, et al. Ready-to-use food supplement, with or without arginine and citrulline, with daily chloroquine in Tanzanian children with sickle-cell disease: a double-blind, random order crossover trial. *Lancet Haematol*. 2018;5(4):147–60.
15. Schnog JB, Jager EH, van der Dijs F, Duits AJ, Moshage H, Muskiet FD, et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. *Ann Hematol*. 2004;83:371–5.
16. Eleutério RMN, Nascimento FO, Araújo TG, Castro MF, Filho TPA, Filho PAM, et al. Double-Blind Clinical Trial of Arginine Supplementation in the Treatment of Adult Patients with Sickle Cell Anaemia. *Adv Hematol*. 2019;p. 6378076. doi:10.1155/2019/4397150.
17. Zolaly M, Al-Mohammadi G, Al-Saadi G, Qasim D. Vaso-occlusive crises in patients with sickle cell disease: Parents' perspectives and association with disease outcomes. *J Taibah Univ Med Sci*. 2019;14(6):515–22.
18. Jesus A, Konstantyner T, Lôbo IKV, Braga JAP. *Rev Paul Pediatr*. 2018;36(4):491–9.
19. Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. *Eur J Haematol*. 2020;105(3):237–46.
20. Rigano P, De Franceschi L, Sainati L, Piga A, Piel F, Cappellini MD, et al. Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia Investigators. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent. *Blood Cells Mol Dis*. 2009;69:82–9. doi:10.1016/j.bcmd.2017.08.017.
21. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. *Annu Rev Pathol*. 2018;14:263–92. doi:10.1146/annurev-pathmechdis-012418-012838.
22. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. *J Clin Invest*. 2017;127(3):750–60.
23. Gürkan E, Ergun Y, Zorludemir S, Başlamişli F, Koçak R. Liver involvement in sickle cell disease. *Turk J Gastroenterol*. 2005;16(4):194–8.
24. Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. *Nat Rev Nephrol*. 2015;11(3):161–71.
25. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. *N Engl J Med*. 2000;342(2):83–9.

Author biography

Subash Chandra Majhi, Associate Professor

Himansu Nayak, Assistant Professor

Sameer Kiro, Assistant Professor

Santosh Patil, Resident

Shitanshu Kumar Meher, Associate Professor

Sanjukta Panda, Associate Professor

Mangal Charan Murmu, Associate Professor https://orcid.org/0000-0003-2606-6545

Cite this article: Majhi SC, Nayak H, Kiro S, Patil S, Meher SK, Panda S, Murmu MC. Arginine in sickle cell vaso-occlusive crisis: A randomised placebo control trial. *Panacea J Med Sci* 2024;14(1):292-300.